Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will
reduce body weight and improve metabolic variables in obese or overweight patients with BP
without worsening psychiatric symptoms. The investigators predict that liraglutide 3.0 mg sc
injection will display greater efficacy as compared to placebo in decreasing body weight in
patients with BP who are obese or overweight. To prove this hypothesis, investigators will
conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm
clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with
stable BP. The investigators have chosen BP rather than another SMI because it is the most
common SMI (more common than schizophrenia or schizoaffective disorder) and has a
particularly strong association with obesity.